CCM
IMVT icon

Coldstream Capital Management’s Immunovant IMVT Stock Holding History

Coldstream Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33
Closed -$564 – 2174
2025
Q1 		$564 Buy
+33
New +$690 ﹤0.01% 3319

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Coldstream Capital Management's IMVT Position: Q2 2025 in Review

Coldstream Capital Management sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 33 shares — an estimated $564 sold.

Coldstream Capital Management first reported a position in IMVT in Q1 2025 and held it in 1 quarter. The position peaked at $564 in Q1 2025. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • Coldstream Capital Management reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 33 Immunovant shares in Q2 2025, an estimated $564.
  • Coldstream Capital Management first reported a position in Immunovant in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Immunovant position peaked at $564 in Q1 2025.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.